Calcium dependent phospholipase A2 activity in the mixed micelies of 1-palmitoyl-2-oleoylphosphatidylglycerol and cholate was measured in sera of 39 patients with Crohn's disease, 40 patients with ulcerative colitis, and 40 healthy controls. The phospholipase A2 activity was significantly raised in those sera of the patients with active Crohn's disease and those with moderate and severe ulcerative colitis. The major phospholipase A2 activity derived from the sera was separated into two peaks by reverse phase high performance liquid chromatography. The phospholipase A2 active fractions were immunochemically characterised using specific antibody directed against human group II phospholipase A2 purified from rheumatoid synovial fluid. The results suggest that raised serum phospholipase A2 activity in patients with Crohn's disease and ulcerative colitis was mainly attributed to the two forms of phospholipase A2 immunochemicaily related to group II enzyme.
Phospholipase A2 hydrolyses the fatty acyl ester bond at the sn-2 position ofglycerophospholipids and produces free fatty acids and lysophospholipids. Cellular calcium dependent phospholipase A2s have been thought to participate in the regulation of the phospholipid metabolism in biomembranes as well as eicosanoid biosynthesis. ' [1] [2] [3] [4] In this context, increased phospholipase A2 activity of ileal and colonic mucosa of Crohn's disease'`6 has been reported. This suggests involvement of phospholipase A2 in the pathogenesis of intestinal inflammation. To clarify the pathophysiological role of phospholipase A2 in inflammatory bowel disease, it is important to examine the relationship between the severity of disease and phospholipase A2 activity levels in serum, and the isozymic nature of phospholipase A2 present in serum ofthe patients with inflammatory bowel disease. Increased serum phospholipase A2 activity has been reported in patients with acute pancreatitis,"7 rheumatoid arthritis," and septic shock.'9 It is, however, unknown what kind of phospholipase A2 contributes to raised serum phospholipase A2 activity. In inflammatory bowel disease, serum phospholipase A2 activity level and the molecular entity of serum phospholipase A2 remain to be examined in detail.
In the present study, we found raised serum phospholipase A2 activity in patients with Crohn's disease and ulcerative colitis. To examine the molecular entity of the increased phospholipase A2, serum phospholipase A2 was immunochemically characterised, after being separated by reverse phase high performance liquid chromatography, by means of immunoblot analysis using a specific antibody directed against group II phospholipase A2 purified from Raised serum activity ofphospholipaseA2 immunochemically related togroup II enzyme in inflammatory bowel disease Phospholipase A2 activity was determined as described previously28 using 0-8 mM l-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) as a substrate in the presence of 5 mM cholate. Fatty acids released by phospholipase A2 were labelled with 9-anthryldiazomethane, and the derivatised fatty acids were separated by high performance liquid chromatography on a Superspher RP-18 (4x50 mm, Merk, Darmstadt, FRG) column and each derivatised fatty acid was quantified using marganic acid as an internal standard. The solvent system used was 98% acetonitrile at a flow rate of 1 ml/min. Calcium dependent phospholipase A2 activity was estimated as the difference between the activity assayed in the presence of 5 mM CaCl2 and that in the presence of 10 mM ethylenediaminetetra acetic acid (EDTA). Calcium independent phospholipase A2 activity was calculated as the difference between the activities in the presence of 10 mM EDTA with and without substrate. The phospholipase A2 activity was expressed as nmoles of oleic acid released/min/ ml. The hydrolysis of POPG by phospholipase A2 in human serum under standard assay conditions proceeded almost linearly during the initial 10% hydrolysis. There was no difference between serum and plasma phospholipase A2 activities in normal controls, patients with Crohn's disease and ulcerative colitis.
The positional specificity of phospholipase A2 action can be determined by this method with a mixed acyl phospholipd as a substrate: the time courses of the hydrolysis at the sn-i position and of that at the sn-2 position are separately followed and compared with those of the hydrolysis by C adamanteus phospholipase A2, which is known to exclusively hydrolyse the ester bond at the sn-2 position. Phospholipase A action of serum was rather specific for the cleavage of the acyl ester bond at the sn-2 position.
The enzyme samples separated by reverse phase high performance liquid chromatography contained acetonitrile. Therefore, we tested the effect of acetonitrile on phospholipase A2 activity. The inclusion of acetonitrile up to about 50% in the assay mixture did not affect enzyme activity.
ASSAY FOR IMMUNOREACTIVE PANCREATIC PHOSPHOLIPASE A2
Serum immunoreactive pancreatic phospholipase A2 (IR-PLA2) was measured by sensitive and specific radioimmunoassay kit for human pancreatic phospholipase A2 (S-0932, Shionogi Pharmaceutical Ltd, Osaka, Japan). The sensitivity of this assay was 71 fmol/ml serum.
We tested the crossreactivity of the antibody against human pancreatic phospholipase A2 used in this kit with purified human group II phospholipase A2. This antibody proved to have no crossreactivity with human group II phospholipase A2 purified from rheumatoid synovial fluid.
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY ANALYSIS OF PHOSPHOLIPASE A2 IN SERUM
The phospholipase A2 in sera of four patients with Crohn's disease and three patients with ulcerative colitis which had the increased phospholipase A2 activity and that in sera of two healthy controls were characterised by reverse phase high performance liquid chromatography. The serum sample diluted two fold with 20 mM Tris-HCl (pH 7.4) was applied to a short S-Sepharose column (6x 10 mm) preequilibrated with 20 mM Tris-HCl (pH 7.4 Those of controls and patients with inactive and active Crohn's disease were 2.0 (0O1), 3.6 (07), and 14-2 (2-1) nmol/min/ml, respectively. As serum phospholipase A2 activity levels in controls apparently obeyed the normal distribution, the mean +2 SD of controls (2.8 nmol/min/ml) was defined as the upper limit of standard range. The activities of the active Crohn's disease patients were significantly higher than those of the inactive Crohn's disease patients (p<0-001) as well as those of the controls (p<0001). Moreover, each activity of all the active Crohn's disease patients was higher than the standard range. No significant difference was found between those of the inactive Crohn's disease patients and those of the controls. No significant difference of serum phospholipase A2 activity levels was found among patients with Crohn's disease treated with no medicine, sulphasalazine, predonisolone, and predonisolone in addition to sulphasalazine. The phospholipase A2 activities of patients with mild, moderate, and severe ulcerative colitis were 2-0 (02), 4.5 (06), and 6.1 (08) nmol/min/ml, respectively. Those of severe ulcerative colitis patients were significantly higher than those of the mild ulcerative colitis patients (p<0-001) and those of the controls (p<0-001). The differences between those of the moderate ulcerative colitis patients and those of the mild ulcerative colitis patients as well as between those of the moderate ulcerative colitis patients and those of the controls were also (Table II) .
Calcium independent phospholipase A2 activity towards mixed micelles of POPG and cholate was found to be very low (<-O002 nmol/ min/ml) in sera of healthy controls and patients with Crohn's disease and ulcerative colitis, and there was no difference in level of this activity among the sera.
CHARACTERISATION OF SERUM PHOSPHOLIPASE A2 OF INFLAMMATORY BOWEL DISEASE PATIENTS
To examine which isozyme of phospholipase A2 is responsible for raised serum phospholipase A2 activity of inflammatory bowel disease patients, we immunochemically characterised the enzyme. We first determined immunoreactive pancreatic phospholipase A2 level in serum by means of a specific radioimmunoassay. No significant difference was found in serum immunoreactive pancreatic phospholipase A2 levels among the healthy controls and the patients with Crohn's disease and ulcerative colitis, and immunoreactive pancreatic phospholipase A2 levels seemed to have no correlation with the disease activity of Crohn's disease and ulcerative colitis (Table III) . Serum immunoreactive pancreatic phospholipase A2 level should not be directly proportional to phospholipase A2 activity, because the antibody used for the present radioimmunoassay system recognises pancreatic prophospholipase A2 as well as pancreatic phospholipase A2. To obtain more direct information on the isozymic nature of serum phospholipase A2, we characterised its activity after separation by reverse phase high performance liquid chromatography as des- 16 patients were raised. In patients with Crohn's disease, correlation was observed between serum phospholipase A2 activity and serum C-reactive protein levels (p<0005), and between serum phospholipase A2 activity levels and erythrocyte sedimentation rate values (r=0-72, p<0-001) (Fig 4A, B) . Serum C-reactive protein levels in patients with active Crohn's disease were significantly higher than those in patients with inactive Crohn's disease (p<0001) as well as erythrocyte sedimentation rate values (p<0005). Of 29 patients with moderate and severe ulcerative colitis, serum phospholipase A2 activity of 24 patients revealed higher levels than the standard range, whereas serum C-reactive protein levels of nine patients and erythrocyte sedimentation rate values of eight patients were 301 A0 raised. In patients with ulcerative colitis, weak correlation (r=056, p<0 001) was found between serum phospholipase A2 activity levels and erythrocyte sedimentation rate values ( Fig  5A, B) (Fig 2) . The enzyme eluted earlier was similar to rheumatoid synovial fluid phospholipase A2 as regards molecular weight, retention time, and immunoreactivity with antisynovial fluid phospholipase A2 antibody, suggesting that this form of serum phospholipase A2 may be identical, or closely related, to group II phospholipase A2 purified from rheumatoid synovial fluid. On the other hand, the group II like phospholipase A2 eluted later seemed to have greater molecular surface hydrophobicity than the one eluted earlier, in spite of having the same apparent molecular weight as the latter (Fig 3A) . The detailed structural differences between the two forms ofgroup II Serum phospholipase A2 activity, of which molecular entity was not known, has been reported to be raised in other inflammatory disease as described above. Therefore, rises in serum phospholipase A2 activity does not seem to be specific to a defined disorder, but rather to be the consequence of intestinal and systemic inflammation. Recent Olaison et al'S reported that increased phos-pholipase A2 activity in ileal mucosa was associated with recurrence of the disease in patients with Crohn's disease. Increased phospholipase A2 activity has also been reported in colonic mucosa of active Crohn's colitis. '6 In these studies, the data for phospholipase A2 activity were reported at rather acidic pH of 6-0 and in the presence of 2 mM CaCl2. Under these conditions alkaline active calcium dependent and calcium independent phospholipase A2S, and lysosomal phospholipase A2s with acidic pH optimum may contribute to the enzyme activity. A large amount of calcium independent phospholipase A2 has been reported to be particularly present in ileal mucosa.4950 This complicated the interpretation of the relationship between raised phospholipase A2 activity in the intestinal mucosa reported' 16 and raised serum group II like phospholipase A2 activity as shown in this study. To clarify the pathophysiological relation between phospholipase A2 activities in serum and intestinal mucosa in inflammatory bowel disease, differential determination of various phospholipase A2 isozymes should be required.
